BPC-157 Side Effects: What the Human Record Actually Shows

Nobody knows BPC-157's side effects in people, because nobody has run a controlled human trial. Three small published reports, 30 people in all, recorded no adverse effects, but none had a comparison group and the largest was a phone survey. FDA's own summary is that it lacks enough information to know whether BPC-157 causes harm in humans.

What a side effect means when there is no controlled trial

On an approved drug, the side-effect list comes from trials that gave some people the drug and some a placebo, then counted what happened in each group. That comparison is what lets a label report how often a reaction happened on the drug against how often it happened anyway.

BPC-157 has no such list. It has never completed a placebo-controlled trial in humans. So "BPC-157 has no side effects," the claim that shows up on forums and product pages, is not a finding. It describes an absence of measurement.

Three things fill the gap, and they are different kinds of evidence:

• Small human reports from clinics, with no control group.
• FDA's written assessment of the risks it could and could not rule out.
• Mechanism and animal work, which can suggest a risk but cannot show one happened.

Every published human report, itemized

A PubMed search for BPC-157 in September 2026 returned 233 records. Almost all are animal or laboratory studies. A systematic review of the literature through June 2024 found one clinical study and no clinical safety data⁴. A 2025 review counted three small human pilot studies and noted that none reported adverse effects⁵. Those three are the whole published human record.

The knee report is the largest. Patients who had received BPC-157, alone or with thymosin beta-4, were phoned and asked to rate their pain before and after. The paper states that no specific tools were used to measure function, stiffness or daily activities¹. A phone call months later is a weak instrument for catching side effects: a patient is unlikely to recall, or connect, a mild reaction from a year earlier.

The bladder study gave 12 women a single procedure and assessed them with a global response questionnaire. It reports that no one dropped out and no adverse events were reported².

The intravenous study infused BPC-157 into two people, both of whom had received it intravenously before. Blood markers for the heart, liver, kidneys, thyroid and glucose did not change, and no side effects were reported. The authors call for further studies to confirm safety³.

Thirty people across three routes, with no comparison group, is enough to say that no dramatic reaction was seen in these patients. It is not enough to say anything about uncommon reactions, slow-developing ones, or what happens with months of use.

What FDA said about BPC-157, and where it sits now

FDA keeps a page of bulk drug substances nominated for compounding that may present significant safety risks. The current version is marked "Content current as of 04/22/2026."

BPC-157 appears on it, in the section headed Bulk drug substances nominated but withdrawn. FDA describes that section as substances previously in category 2 whose nominations "were withdrawn by the nominators"⁶. It is no longer in the active category 2 table.

The risk text FDA published for it is still on the page:

"Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans."

Two points follow. First, a withdrawn nomination is not an approval or a clearance. It means the party that asked for BPC-157 to be considered stopped asking. Second, FDA's concern was never a specific observed injury. It was that nobody had the data to rule injuries out. That is the same gap the three human reports leave open. Our page on what "research chemical" means walks through the rest of that FDA list, and our compounding status table shows where every popular peptide stands today.

The cancer question: a mechanism, not an observation

The most common worry about BPC-157 is cancer, and it comes from how the peptide is thought to work.

In animal and cell studies, BPC-157 activates pathways that grow new blood vessels, notably VEGFR2 signaling and nitric oxide production through the Akt-eNOS axis⁵. New blood-vessel growth, called angiogenesis, is part of why injuries heal. It is also something tumors depend on. A 2026 review of unregulated injectable peptides, BPC-157 among them, lists pathological angiogenesis and carcinogenesis among their potential risks⁷.

Keep the evidence level straight. No human study has reported a cancer linked to BPC-157, and no human study has followed anyone long enough to see one. The concern is a reasonable inference from mechanism. It has not been tested, and the absence of reports tells you little when the total human record is 30 people.

Compare how an approved peptide handles the same kind of worry. Tesamorelin raises a growth factor, IGF-1, and its label makes active cancer a contraindication and tells prescribers to stop the drug if a cancer recurs¹¹. Our tesamorelin side effects page covers that label in full. BPC-157 has no label, so nobody has written its equivalent.

Product quality is a separate risk

FDA's text flags two problems that have nothing to do with how BPC-157 acts in the body: peptide-related impurities and API characterization, meaning confirming what the powder actually is⁶.

Those are manufacturing risks, and they apply before the first injection. BPC-157 is sold research-use-only, which means no one is certifying identity, purity, sterility or endotoxin levels for human use. A reaction to a contaminated vial would be a real side effect of what the buyer injected, whether or not the peptide itself caused it.

This is why the three clinical reports tell you little about a product bought online. The bladder study specifies BPC-157 made by a 503A compounding pharmacy². What a reader orders from a research-chemical site is a different product with a different risk. Our guide to certificates of analysis covers what a testing sheet can and cannot prove.

The trials that could change this

A ClinicalTrials.gov search in September 2026 for BPC-157, under three spellings, returned the same four registered studies each time. A control search for semaglutide in the same pass returned 789, so the search was working.

The hamstring trial is the one to watch. It randomizes people with a grade II hamstring strain to BPC-157 or placebo for 14 days alongside standard rehabilitation, with return to sport and MRI injury volume as its co-primary endpoints⁸. A placebo arm of that size would produce the first real comparison of side effects in people. The rotator cuff pilot describes BPC-157 as not yet studied in formal human clinical trials⁹. The 2015 phase 1 safety study has never posted results¹⁰.

What to take from it

The honest answer to "what are the side effects of BPC-157" is that they have not been measured. Three uncontrolled reports found nothing, which is weak reassurance at best. FDA said it could not tell whether the drug causes harm. The one serious theoretical concern, cancer through new blood-vessel growth, has not been tested in either direction.

If you are recovering from an injury, our injury recovery guide covers what has been tested in people. The BPC-157 page has the full evidence record, and our reading of the healing-peptide evidence explains why the animal results have not yet translated into trials. The popular wolverine stack pairs BPC-157 with TB-500, and that combination has no human record at all.